NON-INVASIVE MRI LIVER FIBROSIS DEVICE PRELIMINARY EPOC STUDY RESULTS & CAPITAL RAISING PRESENTATION | OCTOBER 2026 Funding three growth programmes from a profitable, cash-generative base Andrew Harrison | MD & CEO Benjamin Carruthers | CFO Resonance Health Ltd (ASX:RHT) CONFIDENTIAL - NOT FOR...
Investor Presentation Liver Fibrosis Device & Capital Raise
Filed with ASX ·
6ix is reading this filing.
In the deck
Earlier from Resonance Health
- $6.0 Million Placement Oversubscribed
- Liver Fibrosis Device - EPoC Study Results
- Trading Halt
- Global Strategic Alliance & MSA with Image Analysis Group
- FY26 Full Year Results & Investor Webinar
Later from Resonance Health
All Resonance Health news releasesFollow Resonance Health into a list and get an email when it puts out news.
Follow Resonance Health